Skip to main content

Search

Reset all filters
482 Result(s)
Sort by

FDA approved treatment option for adults with CKD

FDA approved treatment option for adults with CKD

The FDA has approved Jardiance® (empagliflozin) tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression.
We support non-linear career paths.

We support non-linear career paths.

Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction